A re-analysis of a clinical trial of GlaxoSmithKline's antidepressant Seroxat suggests the drug is ineffective and unsafe in younger patients, contradicting its earlier conclusions. The new study ...

This website uses cookies to ensure you get the best experience. By using our website, you agree to our Privacy Policy ...

GSK forecast sales in 2025 to grow 3%-5% and reported better-than-expected fourth-quarter earnings, as strength in its HIV ...

In October, the MHRA reviewed data from the earliest trials of Seroxat. The information was supplied by GlaxoSmithKline in the late Eighties, and it was the MHRA's responsibility to analyse the ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. GSK is nearing a $1bn deal to buy a US biotech developing a treatment for rare gastrointestinal tumours ...

January 13, 2025--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-based ...

Pharmaceutical giant GSK and the University of Oxford are creating a new cancer vaccine to prevent the disease from developing. The partnership intends to create a vaccine or vaccines which target ...